Topiramate and Oral Cleft
According to the American Dental Association (ADA), pregnant women who take the drug Topiramate increase the risks of oral cleft in babies. This conclusion stems from data the North American Antiepileptic Drug Pregnancy Registry collected, which the Food and Drug Administration (FDA) released in a safety alert. Risk extends to generic versions of Topiramate, as well.
Topiramate is a drug that treats epileptic seizures. The drug increases risks of cleft lip in newborns when its consumption occurs during the first trimester of pregnancy. In the article cited in the previous paragraph, the ADA explains that, "infants exposed to Topiramate as a single therapy experienced a 1.4 percent prevalence of oral clefts, compared with a prevalence of 0.38 percent - 0.55 percent in infants exposed to other antiepileptic drugs..."